Prospective study of [18F]fluorodeoxyglucose positron emission tomography/computed tomography for staging of muscle-invasive bladder carcinoma.

PURPOSE Novel imaging modalities are needed to detect occult metastatic disease in bladder carcinoma. Patients with regional lymphatic spread could be targeted for neoadjuvant chemotherapy, and patients with distant metastatic disease could be spared the unnecessary morbidity of radical cystectomy. Herein, we report a prospective study of positron emission tomography/computed tomography (PET/CT) with [(18)F]fluorodeoxyglucose (FDG) in patients undergoing radical cystectomy for cT2-3N0M0 urothelial carcinoma of the bladder. METHODS Forty-three chemotherapy-naïve patients underwent FDG-PET/CT before planned cystectomy. All had negative conventional CT and bone scintigraphy before enrollment. Positive FDG-PET/CT was confirmed by percutaneous biopsy or open surgical exploration, whereas negative FDG-PET/CT was confirmed by complete lymphadenectomy. Recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) were described using the Kaplan-Meier method and compared using log-rank test. RESULTS Median follow-up was 14.9 months (range, 0.4 to 46.1 months). One patient who did not undergo lymphadenectomy was excluded from the pathology data analysis (n = 42), whereas another patient who failed to return for follow-up was excluded from survival analysis (n = 42). FDG-PET/CT demonstrated a positive predictive value of 78% (seven of nine), a negative predictive value of 91% (30 of 33), sensitivity of 70% (seven of 10), and specificity of 94% (30 of 32). RFS, DSS, and OS were all significantly poorer in the patients with positive FDG-PET/CT than in those with negative FDG-PET/CT. CONCLUSION FDG-PET/CT detected occult metastatic disease in seven of 42 patients with negative conventional preoperative evaluations. PET findings were strongly correlated with survival. As such, FDG-PET/CT may help in making treatment decisions before radical cystectomy.

[1]  Thomas F Hany,et al.  Integrated PET/CT: current applications and future directions. , 2006, Radiology.

[2]  R. Berg,et al.  A Systematic Review and Meta-analysis , 2010 .

[3]  J. Chin,et al.  Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: a systematic review and meta-analysis. , 2004, The Journal of urology.

[4]  J. Albanell,et al.  Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. , 2009, Critical reviews in oncology/hematology.

[5]  Lantz Ej,et al.  Diagnostic imaging of urothelial cancer. , 1984 .

[6]  A. Moss,et al.  MR staging of bladder carcinoma: correlation with pathologic findings. , 1988, Radiology.

[7]  R. Coleman,et al.  The National Oncologic PET Registry (NOPR): Design and Analysis Plan , 2007, Journal of Nuclear Medicine.

[8]  M. Resnick,et al.  Limitations of computerized tomography in staging invasive bladder cancer before radical cystectomy. , 2000, The Journal of urology.

[9]  A. Jemal,et al.  Cancer Statistics, 2008 , 2008, CA: a cancer journal for clinicians.

[10]  Bruce D Cheson,et al.  Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development , 2005, Clinical Cancer Research.

[11]  G. Griffiths.  Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists , 1999 .

[12]  M. Terris,et al.  Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of transitional cell carcinoma. , 2003, Advances in experimental medicine and biology.

[13]  L. Mortelmans,et al.  FDG-PET for preoperative staging of bladder cancer , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  P. Alken,et al.  Computerized tomography: an unreliable method for accurate staging of bladder tumors in patients who are candidates for radical cystectomy. , 1989, The Journal of urology.

[15]  Nicholas J Vogelzang,et al.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. , 2003, The New England journal of medicine.

[16]  J. Thüroff,et al.  Lymphadenectomy in patients with transitional cell carcinoma of the urinary bladder; significance for staging and prognosis , 2000, BJU international.

[17]  U. Studer,et al.  Pelvic lymph node metastases from bladder cancer: outcome in 83 patients after radical cystectomy and pelvic lymphadenectomy. , 2002, The Journal of urology.

[18]  A. Lammertsma,et al.  Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-d-glucose and positron emission tomography: an overview of different analytical methods , 2000, European Journal of Nuclear Medicine.

[19]  N. Arikan,et al.  Staging with computed tomography, transrectal ultrasonography and transurethral resection of bladder tumour: comparison with final pathological stage in invasive bladder carcinoma. , 1996, British journal of urology.

[20]  S. Groshen,et al.  Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  C. Vale.  Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis , 2003, The Lancet.

[22]  R. Babaian,et al.  Incidence, extent and location of unsuspected pelvic lymph node metastasis in patients undergoing radical cystectomy for bladder cancer. , 1987, The Journal of urology.

[23]  P. Conti,et al.  [F-18]-Fluorodeoxyglucose PET and PET-CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma , 2008, International Journal of Clinical Oncology.